Abstract 430P
Background
The emetogenic classification of antineoplastic agents has provided a framework for defining antiemetic treatment recommendations in international guidelines. The most widely used classification schema identified four emetic risk levels. However, information on the emetogenicity of each chemotherapeutic regimen is insufficient. We previously reported that the emetic risk of pemetrexed was higher than that of taxans. Risk factors for chemotherapy-induced nausea and vomiting (CINV) were also assessed in patients with lung cancer receiving carboplatin plus pemetrexed (CBDCA+PTX) or carboplatin plus paclitaxel (CBDCA+PEM), and the CINV incidence was compared between these two regimens.
Methods
Data were pooled from two prospective studies, and propensity score matching was used to compare the CINV incidence between CBDCA+PTX and CBDCA+PEM groups. Risk factors for CINV were identified using logistic regression models. The pattern of CINV occurrence was evaluated by 7-day patient diary for recording CINV after the commencement of chemotherapy.
Results
Among 240 evaluable patients, the CINV incidence was higher in the CBDCA+PEM group than in the CBDCA+PTX group at the delayed phase (nausea: 51.1% vs. 36.2%, P = 0.040; vomiting: 23.4% vs. 14.9%, P = 0.138). The pattern of delayed CINV occurrence peaked on days 5 and 4 for CBDCA+PEM and CBDCA+PTX regimens, respectively. Logistic regression analysis identified younger age, female sex, no alcohol consumption, two antiemetics, and CBDCA+PEM regimen as independent risk factors associated with delayed nausea, and female sex and two antiemetics for delayed vomiting.
Conclusions
The emetic risk of CDBCA+PEM regimen was higher than that of CBDCA+PTX regimen. More aggressive antiemetic prophylaxis such as quadruple therapy, including olanzapine, may be considered in patients receiving CDBCA+PEM regimen.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
396P - Determinants of visiting a referral hospital for cervical cancer screening at Uganda Cancer Institute
Presenter: Collins Mpamani
Session: Poster display session
Resources:
Abstract
397P - Development of prediction model for hepatocellular carcinoma in chronic hepatitis B patients
Presenter: Teerapat Ungtrakul
Session: Poster display session
Resources:
Abstract
398P - Planning for future cancer control programs in Uganda: Projections of top five cancers’ incidence in the next decade
Presenter: Judith Asasira
Session: Poster display session
Resources:
Abstract
399P - Prevalence of colorectal cancer risk factors in apparently healthy adults in Suluhan Village, Bali
Presenter: Cindy Trisina
Session: Poster display session
Resources:
Abstract
400P - Female lung cancer: Emerging issue in Bangladesh
Presenter: Muhammad Rafiqul Islam
Session: Poster display session
Resources:
Abstract
402P - Work-related outcomes among cancer survivors in Singapore
Presenter: Chia Jie Tan
Session: Poster display session
Resources:
Abstract
407P - Focal treatments for metastatic soft tissue sarcoma (mSTS) is associated with improved overall survival
Presenter: Ching Tso Chen
Session: Poster display session
Resources:
Abstract
408P - The Asian sarcoma consortium sarcoma preceptorship program: A program evaluation study utilizing the Kirkpatrick model (Level 1 and 2)
Presenter: Fernando Gracieux Jr.
Session: Poster display session
Resources:
Abstract
409P - Integrated genomic and transcriptomic analysis revealed mutagenic patterns of dedifferentiated liposarcoma and leiomyosarcoma in Chinese patients
Presenter: Yuhong Zhou
Session: Poster display session
Resources:
Abstract
410P - Treatment patterns and outcomes of elderly patients with metastatic soft tissue sarcomas (mSTS)
Presenter: Yu-ju Kuo
Session: Poster display session
Resources:
Abstract